<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-19_08-18-02</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Platinum-resistant recurrent ovarian clear cell carcinoma with multifocal metastases and severe anemia requires palliative, symptom-focused care, with systemic intensity guided by ECOG/frailty and pending MSI status. Key uncertainties are performance status, anemia etiology, and how aggressively to pursue non-platinum systemic therapy versus local RT.

Core Treatment Strategy:
- Immediately optimize anemia with transfusion and basic workup; reassess ECOG and frailty before any systemic therapy or RT. [@20230103|2023-01-03]  
- Manage as platinum-resistant clear cell carcinoma; plan dose-attenuated non-platinum systemic therapy after stabilization, including clinical-trial evaluation. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]  
- Use current CT/MRI to plan palliative RT to presacral/rectal and sacral/right iliac lesions, coordinated with pain/supportive care. [@2022-12-29|MR][@2022-12-29|CT]  
- Proceed with formal MSI testing and schedule interval imaging for hepatic/pelvic disease and splenic lesion evolution. [@report_id:OH2203828|2022-04-18]  

Change Triggers:
- If ECOG is poor or anemia remains severe despite optimization, de-escalate to best supportive care with minimal or no systemic therapy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]  
- If new symptoms or imaging raise uncertainty about additional targets, reconsider PET-CT only if results will change RT fields or systemic-versus-local strategy. [@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|18]</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）术后白紫+卡铂化疗6程，末次：2022.8.172022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)MR（2022.07.17）：2022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)肿瘤标志物（2022.10.12）：CA19-9:77.20U/ml↑,CA125:89.60U/ml↑,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(绝经前)↑,ROMA.:36.67%(绝经后)↑。CT（2022.10.25）：肝内多发结节，部分较前新见，转移可能，请结合MR检查。另见肝囊肿同前。MR（2022.10.24）：盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。盆腔系膜多发强化小结节，转移可能。2022.11.10外院血常规：白细胞 2.36，红细胞 3.56，血红蛋白 97，血小板 153外院生化：ALP　105，NA 136，PAB 1242022.11.30外院血常规：白细胞 3.46，红细胞 3.48，血红蛋白 94，血小板 1342022.11.17外院肿瘤指标：CA125　403，Ca153　63.8，Ca199 96.8，Ca724 695肿瘤标志物（2022.12.29）：CA19-9:229.00U/ml↑,CA125:933.00U/ml↑,CA15-3:86.00U/ml↑,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/L↑,ROMA:41.02%(绝经前)↑,ROMA.:85.98%(绝经后)↑。MR（2022.12.30）：盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。右侧髂骨新见强化结节，转移可能。盆腔系膜多发强化小结节同前相仿，转移可能。直肠局部肠壁增厚伴强化。CT（2022.12.30）：肝内多发转移结节，较前增多，部分较前增大。另见肝囊肿同前。脾脏片状影，脾脏梗塞？随访。咨询报告</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;白紫+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;histology&quot;:&quot;首先考虑为透明细胞癌&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;卵巢癌复发&quot;,&quot;site&quot;:&quot;卵巢&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;白紫+卡铂&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml (2022-10-12)&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;CA125:89.60U/ml&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;45.7&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;161&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;562&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-11-10&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;97&quot;},{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-11-30&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;94&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary debulking surgery&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising CA125&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;白紫+卡铂 (6 cycles)&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;高级别腺癌&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(部分+)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(少弱+)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;(+/-)&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;(60%+)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(灶+)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;intestinal wall full thickness&quot;,&quot;peritoneum (left retroperitoneal tumor)&quot;,&quot;vagina (partial)&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7*4*2.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Molecular/genetic testing not reported&quot;,&quot;Definitive origin laterality not specified&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;sacrum&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Pelvis post-op changes&quot;,&quot;presacral mass, consider recurrence with adjacent sacral involvement&quot;,&quot;multiple enhancing small mesenteric nodules in pelvis, suggest metastases&quot;],&quot;impression&quot;:&quot;Recurrence with possible sacral involvement and pelvic mesenteric metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple hepatic nodules, some new compared to prior&quot;,&quot;hepatic cysts unchanged&quot;],&quot;impression&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;pelvis&quot;,&quot;right iliac bone&quot;,&quot;sacrum&quot;,&quot;rectum&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral mass increased in range with heterogeneous enhancement&quot;,&quot;new enhancing nodule in right iliac bone&quot;,&quot;multiple pelvic mesenteric enhancing nodules&quot;,&quot;rectal local bowel wall thickening with enhancement&quot;],&quot;impression&quot;:&quot;Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;liver&quot;,&quot;spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size&quot;,&quot;patchy splenic shadow, possible splenic infarct&quot;],&quot;impression&quot;:&quot;Progressive hepatic metastases; splenic abnormality noted, follow-up suggested&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last administration recorded 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Tumor markers rising after chemotherapy&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:&lt;0.91ng/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, AFP&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new, likely metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver lesions, consider metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Tumor markers markedly elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;CA125, CA19-9, HE4, CA15-3&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis, CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: 复发转移性卵巢透明细胞癌、已接受含铂一线化疗且进展，符合妇科恶性肿瘤晚期且标准治疗失败后＞1线的入组设定。
- Missing eligibility confirmations (0-2 items):
  - 受试者一般情况及重要脏器功能是否符合I期试验要求
  - 是否存在其他未披露的排除性合并症或活动性感染</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before committing to any non-platinum regimen, please clarify ECOG status, symptom burden, and plan to correct severe anemia (Hgb 74 g/L) including transfusion and basic workup, as current marrow reserve may not safely support standard-intensity therapy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Given progressive pelvic, hepatic, and new bone lesions, please state whether you believe PET-CT would practically alter local vs systemic treatment planning now, or if current MRI/CT are sufficient for RT and systemic decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before finalizing a non-platinum palliative regimen, we urgently need ECOG status, detailed symptoms, and full anemia workup/optimization given Hgb 74 g/L, as current toxicity may preclude standard systemic dosing.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Please advise whether PET-CT is likely to change management in this multifocal metastatic clear cell ovarian carcinoma (including bone) versus relying on existing imaging for palliative systemic/local planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Latest MRI/CT show progressive presacral mass with rectal wall thickening and new right iliac bone lesion; please clarify if there are current pelvic/neurologic or bowel obstruction symptoms to prioritize local RT or decompression planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>Given multifocal liver, pelvic, and new osseous metastases, a PET-CT could better delineate whole-body and bone disease burden if results would modify RT fields or systemic vs local strategy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Current pathology indicates clear cell ovarian origin with MMR proficiency and HRD negativity; please ensure all future management uses this histotype assumption.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>MSI status is still unknown; if considering immunotherapy or trials, please request formal MSI/MMR molecular testing beyond IHC alone.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Please prioritize documentation of ECOG and pelvic/neurologic/bowel symptoms and initiate evaluation and correction of severe anemia before confirming systemic regimen and RT sequencing.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>If PET-CT is pursued, please focus the report on whether findings would expand, reduce, or redefine potential RT fields and systemic vs local priorities.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Systemic therapy choice and timing depend critically on ECOG status, pelvic/neurologic and bowel obstruction symptoms, and anemia workup; these should be clarified before committing to a specific non-platinum palliative regimen or RT sequence.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Please proceed with formal MSI testing as suggested; MSI result will materially influence consideration of immunotherapy or relevant clinical trials in this platinum-resistant clear cell setting.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>From a nuclear perspective, PET-CT is most valuable here if its findings would alter RT fields or shift systemic-versus-local priorities; please clarify intended use before ordering.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Treat as platinum-resistant recurrent clear cell ovarian carcinoma with liver, pelvic, bone metastases; prioritize palliative-intent systemic therapy plus symptom control. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18; @pubmed:33758607]  \n\n- Obtain ECOG status, detailed symptoms (pain, bowel/bladder, bleeding), updated renal function, coagulation, and discuss clinical-trial eligibility before selecting regimen.  \n\n- Coordinate with radiation and pain teams for potential local treatment of sacral/iliac lesions and rectal involvement to prevent neurologic/obstructive complications.&quot;,
  &quot;oncologist&quot;: &quot;- Rapid biochemical and radiologic relapse ~2 months after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non-platinum relapse therapy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]\n\n- Current severe anemia (Hgb 74 g/L) may limit intensive systemic therapy; optimize transfusion/iron workup before starting next regimen. [@20230103|2023-01-03]\n\n- Missing: ECOG status, current symptoms, detailed imaging of hepatic/pelvic disease burden, prior maintenance use, and full renal/hematologic toxicity profile.&quot;,
  &quot;radiologist&quot;: &quot;- Progressive pelvic recurrence with enlarging presacral mass, rectal wall thickening, mesenteric nodules, and new right iliac bone lesion. [@2022-12-29|MR]\n\n- Worsening multifocal liver metastases with increased number/size; stable hepatic cysts. [@2022-10-24|CT][@2022-12-29|CT]\n\n- New patchy splenic low-density area suspicious for infarct; recommend imaging follow-up to confirm evolution/complications. [@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|18]&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support metastatic ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@report_id|2022-03-28].  \n\n- MMR proteins intact on IHC (MLH1/MSH2/MSH6/PMS2 positive); MSI status by molecular assay not reported and should be updated [@report_id|2022-03-28].  \n\n- HRD negative; germline ATM p.Y316C VUS, BRCA1/2 and common HR genes without pathogenic variants [@report_id:OH2203828|2022-04-18].&quot;,
  &quot;nuclear&quot;: &quot;- No PET-CT available; cannot assess whole-body metabolic disease or confirm hepatic, pelvic, sacral, iliac, splenic involvement—PET-CT needed.  \n\n- Cross-sectional imaging shows progressive pelvic recurrence with suspected peritoneal, sacral, right iliac bone and hepatic metastases; PET would refine staging. [@2022-12-29|MR][@2022-12-29|CT]  \n\n- PET-CT is valuable to detect extra-pelvic and osseous metastases and guide management in recurrent pelvic malignancy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Confirm ECOG, pelvic/neurologic/bowel symptoms, and complete anemia workup/correction (Hgb 74 g/L) before systemic or RT decisions. [@20230103|2023-01-03]  \n\n- Plan palliative, non-platinum systemic approach for platinum-resistant clear cell ovarian carcinoma after stabilization, with clinical-trial consideration. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18; @pubmed:33758607]  \n\n- Use current MRI/CT to triage sacral/iliac/rectal RT for symptom prevention; reserve PET-CT only if results would change fields/strategy. [@2022-12-29|2022-12-29]&quot;,
    &quot;oncologist&quot;: &quot;- Optimize anemia with transfusion and basic workup, then document ECOG and detailed pelvic/neurologic/bowel symptoms before systemic therapy choice. [@20230103|2023-01-03; @guideline:nccn_ovariancancer_v3_2025__v00000000|18]\n\n- Treat as platinum‑resistant recurrent clear cell ovarian carcinoma with palliative‑intent non‑platinum systemic therapy, considering dose reduction for frailty. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\n- Coordinate with radiation and nuclear medicine: consider PET-CT only if it will modify RT fields or systemic‑versus‑local strategy.&quot;,
    &quot;radiologist&quot;: &quot;- Current MRI/CT sufficiently define pelvic, hepatic, and osseous disease for RT planning; PET-CT reserved for unclear fields. [@2022-12-29|MR][@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|18]\n\n- Highlight progressive presacral mass with rectal wall thickening and sacral/right iliac involvement for consideration of palliative RT to prevent obstruction/neurologic compromise. [@2022-12-29|MR]\n\n- Recommend follow-up imaging of splenic low-density lesion to confirm infarct evolution and exclude further complications. [@2022-12-29|CT]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm ECOG, detailed pelvic/neurologic/bowel symptoms, and complete anemia workup/optimization before finalizing non-platinum palliative regimen and RT sequence [@guideline:nccn_ovariancancer_v3_2025__v00000000|18].  \n\n- Proceed with formal MSI testing to complement intact MMR IHC, as MSI result may affect trial/strategy considerations [@report_id|2022-03-28].  \n\n- Request radiology/nuclear input on whether PET-CT will materially redefine RT fields or systemic-vs-local priorities before ordering imaging (date unknown).&quot;,
    &quot;nuclear&quot;: &quot;- Proceed with PET-CT only if results could change systemic-versus-local priorities or modify planned RT fields, given existing CT/MR detail. [@2022-12-29|MR][@2022-12-29|CT]  \n\n- When PET-CT is done, report should explicitly state whether findings warrant expansion, reduction, or redefinition of candidate RT volumes. [@2022-12-29|MR]  \n\n- PET-CT is guideline-supported to refine extra-pelvic and osseous staging in recurrent ovarian cancer, potentially impacting palliative RT planning. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Optimize anemia and frailty assessment (CBC shows Hgb 74 g/L) and document ECOG/symptoms before systemic or RT decisions. [@20230103|2023-01-03]  \n\n- Plan palliative, non-platinum systemic therapy for platinum-resistant clear cell ovarian carcinoma, considering dose attenuation and clinical-trial options. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18; @pubmed:33758607]  \n\n- Use current CT/MRI to design palliative RT to presacral/rectal and sacral/right iliac lesions; reserve PET-CT for strategy-changing scenarios. [@2022-12-29|2022-12-29]&quot;,
    &quot;oncologist&quot;: &quot;- Optimize severe anemia (Hgb 74 g/L) with transfusion and workup, then document ECOG and symptoms to guide therapy intensity. [@20230103|2023-01-03; @guideline:nccn_ovariancancer_v3_2025__v00000000|18]\n\n- Manage as platinum-resistant recurrent clear cell ovarian carcinoma with palliative-intent, dose-adjusted non-platinum systemic therapy after anemia correction and frailty assessment. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\n- Use current CT/MRI to plan palliative RT to presacral/rectal and sacral/right iliac lesions; reserve PET-CT for management-changing scenarios.&quot;,
    &quot;radiologist&quot;: &quot;- Use existing CT/MRI to plan palliative RT to presacral/rectal and sacral/right iliac lesions; PET-CT only if field-changing. [@2022-12-29|MR][@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|18]\n\n- Arrange interval imaging to reassess hepatic metastatic burden and pelvic disease progression for ongoing palliative planning. [@2022-12-29|CT][@2022-12-29|MR]\n\n- Schedule follow-up imaging of splenic low-density lesion to confirm infarct evolution and detect possible complications. [@2022-12-29|CT]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm ECOG, detailed pelvic/neurologic/bowel symptoms, and complete anemia workup/optimization before finalizing non-platinum palliative systemic regimen and RT sequence [@guideline:nccn_ovariancancer_v3_2025__v00000000|18].  \n\n- Proceed with formal MSI testing in this MMR-proficient, HRD-negative clear cell carcinoma to refine eligibility for trials/strategies [@report_id:HI22-06789|2022-03-28].  \n\n- Use current CT/MRI to plan palliative RT to presacral/rectal and sacral/right iliac lesions; reserve PET-CT for management-changing scenarios (date unknown).&quot;,
    &quot;nuclear&quot;: &quot;- Defer PET-CT for now; current CT/MRI adequately support palliative RT planning to pelvic and right iliac lesions. [@2022-12-29|MR][@2022-12-29|CT]  \n\n- Reconsider PET-CT only if new questions arise about additional RT targets or systemic-versus-local strategy that CT/MRI cannot resolve. [@2022-12-29|MR]  \n\n- Selective PET-CT use in recurrent ovarian cancer is guideline-consistent when results are expected to alter management. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-4-6：肝内多发低密度结节，边界不清，大者约16mm*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常，左输尿管内见支架管影。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发结节，部分较前新见，转移可能，请结合MR检查。 另见肝囊肿同前。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Ovarian clear cell carcinoma, platinum-refractory after 6 cycles carboplatin; metastases to liver, pelvis/presacral area, mesentery, possible sacrum/right iliac bone; MMR intact (MLH1/MSH2/MSH6/PMS2+); need systemic options and trial eligibility given progression shortly post-platinum; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6559 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …
[2] score=0.6533 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 11] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|11]
    cytoreduction o Residual ChT toxicity o The patient’s general condition and preferences  Patients with ﬁrst relapse of ovarian cancer after &gt;6 months of last platinum administration should be evalu- ated by a gynaecological oncology centre experienced in surgery for ovarian cancer to identify poten…
[3] score=0.6399 nccn_ovariancancer_v3_2025__v00000000 [PAGE 18] [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[4] score=0.6345 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[5] score=0.6304 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.6990 PMID 36591227 [@pubmed:36591227]
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
    Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radi…
[2] score=0.6942 PMID 33758607 [@pubmed:33758607]
    Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometr…
[3] score=0.6897 PMID 35401005 [@pubmed:35401005]
    Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
    Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The…
[4] score=0.6785 PMID 30109783 [@pubmed:30109783]
    Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
    NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of hetero…
[5] score=0.6770 PMID 37901720 [@pubmed:37901720]
    Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.
    Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.            In our hospital, we recently summa…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.655937910079956,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.653304398059845,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;cytoreduction\no Residual ChT toxicity\no The patient’s general condition and preferences\n\u0004 Patients with ﬁrst relapse of ovarian cancer after &gt;6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.639877438545227,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 18,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2– IC3\nStage IA\nIB, IC1\nStage II–IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.634539783000946,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.630353569984436,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6990234685355516,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;36591227&quot;,
    &quot;title&quot;: &quot;Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Advanced endometrial clear cell carcinoma (CCC) tends to have poor prognosis owing to aggressive clinical behavior and poor response to conventional chemotherapy. Herein, we report a case of platinum-refractory recurrent ECCC successfully treated with the combination of pembrolizumab, localized radiotherapy and a few cycles of chemotherapy with an extremely durable response even after cessation of immunotherapy for 3 years at the time of publication.&quot;,
    &quot;journal&quot;: &quot;Front Immunol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fimmu.2022.1079253&quot;,
    &quot;impact_factor&quot;: 5.9,
    &quot;similarity&quot;: 0.6990234685355516
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6942298445138815,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33758607&quot;,
    &quot;title&quot;: &quot;Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1β, and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.&quot;,
    &quot;journal&quot;: &quot;J Cancer&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.7150/jca.53395&quot;,
    &quot;impact_factor&quot;: 3.2,
    &quot;similarity&quot;: 0.6942298445138815
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.689679727318789,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35401005&quot;,
    &quot;title&quot;: &quot;Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.&quot;,
    &quot;abstract&quot;: &quot;Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The patient received primary cytoreductive surgery with adjuvant chemotherapy and remained disease-free for four months. She then experienced retroperitoneal lymph node recurrence and was treated with liposomal doxorubicin chemotherapy followed by secondary debulking surgery. The patient experienced a second relapse in the lower left lung 11 months later. Genomic profiling of tumor samples revealed a deleterious AT-rich interactive domain 1A (ARID1A) mutation and homologous recombination deficiency. Thus, the triplet combination of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib; the PD-1 inhibitor, pembrolizumab; and the antiangiogenic agent, bevacizumab was administered. The patient achieved partial response, which was sustained for 12 months. Our study provides the first clinical evidence that the combination of olaparib with pembrolizumab and bevacizumab could be an effective treatment for patients with platinum-resistant, recurrent OCCC.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S362267&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.689679727318789
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6784769128270818,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;30109783&quot;,
    &quot;title&quot;: &quot;Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.&quot;,
    &quot;abstract&quot;: &quot;NUCOLL43 is a novel ovarian clear cell carcinoma (O-CCC) cell line that arose from a primary culture of a patient&#x27;s malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of heterozygosity (LOH) affecting approximately 85% of the genome, mostly copy neutral and almost identical to the original tumor. The cells express epithelial (pan-cytokeratin) and mesenchymal (vimentin) characteristics, CA125 and p16, like the original tumor. They also express ARID1A but not HNF-1β and, like the original tumor, and are negative for p53 expression, with no evidence of p53 function. NUCOLL43 cells express all other DNA damage response proteins investigated and have functional homologous recombination DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP-BEZ235. The NUCOLL43 cell line represents a distinct subtype of O-CCC that is p53 and HNF-1β null but expresses ARID1A. Its high degree of similarity with the original tumor genomically and proteomically, as well as the high level of LOH, make this an interesting cell line for O-CCC research. It has been deposited with Ximbio.&quot;,
    &quot;journal&quot;: &quot;Cancer Med&quot;,
    &quot;pub_date&quot;: &quot;2018-09-01&quot;,
    &quot;doi&quot;: &quot;10.1002/cam4.1724&quot;,
    &quot;impact_factor&quot;: 3.1,
    &quot;similarity&quot;: 0.6784769128270818
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6769791183501056,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;37901720&quot;,
    &quot;title&quot;: &quot;Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.&quot;,
    &quot;abstract&quot;: &quot;Endometriosis-associated ovarian cancer (EAOC) is rare, occurring approximately in 1% of women with ovarian endometriosis. The main histological types are endometrioid adenocarcinoma and clear cell carcinoma (CCC), with the latter being the least common.\n          \nIn our hospital, we recently summarized two patients with ovarian clear cell carcinoma with similar characteristics. They all had endometriosis for a long time and had undergone ovarian cyst removal due to a chocolate cyst. Unfortunately, the cyst recurred after surgery, and the histological diagnosis was clear cell carcinoma. In case 1, the expression of P53 was found in the tumor by regular examination, and the stage was IIB. In Case 2, we found it in intraoperative freezing; the stage was IA. Case 1 has been treated with the TP regimen six times, and the survival period has reached one year. Case 2 had a survival period of 6 years after completing six TP regimen treatments. Clinicians should pay attention to patients with a long history of endometriosis and postoperative recurrence of ovarian cysts accompanied by serum CA-125 of more than 200U/mL. Imaging examination has a good prospect in diagnosing malignant transformation of endometriosis, especially PET-CT.\n          \nThis case report highlights the risk factors related to the formation of ovarian clear cell carcinoma and suggests that the follow-up of patients with ovarian endometriosis is essential because of its recurrence characteristics. Radical surgery and postoperative platinum-containing chemotherapy are the primary treatment methods at present.&quot;,
    &quot;journal&quot;: &quot;Int J Womens Health&quot;,
    &quot;pub_date&quot;: &quot;2023-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/IJWH.S418135&quot;,
    &quot;impact_factor&quot;: 2.6,
    &quot;similarity&quot;: 0.6769791183501056
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- Selection between PARP inhibitors and anti-VEGF therapy at relapse should consider histotype, BRCA1/2 status, prior PARPi/bevacizumab exposure, and cumulative platinum exposure, as these factors influence benefit and toxicity in recurrent epithelial ovarian cancer. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10]

- For first relapse occurring &gt;6 months after last platinum, referral to an experienced gynecologic oncology center for evaluation of secondary cytoreduction is recommended, with decisions guided by likelihood of complete resection, residual toxicity, performance status, and patient preference. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|11]

- NCCN emphasizes that “platinum-sensitive” vs “platinum-resistant” status is a spectrum; clinicians should apply judgment and flexibility when selecting systemic therapy, especially where data are limited (e.g., low-grade or clear cell histologies), and should incorporate maintenance strategies and surveillance accordingly. [@guideline:nccn_ovariancancer_v3_2025__v00000000|18]

- NCCN notes limited data for primary and maintenance therapy in recurrent/persistent low-grade or clear cell ovarian cancers and recommends individualized treatment planning, including consideration of systemic therapy options, clinical trials, and close monitoring during and after treatment. [@guideline:nccn_ovariancancer_v3_2025__v00000000|14]

- For first recurrence, platinum-based chemotherapy is the preferred option (category 1) when appropriate, with consideration of secondary cytoreductive surgery and/or best supportive care; immediate platinum-based recurrence therapy may also be used as a category 2B option depending on clinical context. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]

- A case report in platinum-refractory metastatic endometrial clear cell carcinoma showed a durable response to pembrolizumab combined with localized radiotherapy, suggesting potential benefit of immunotherapy plus radiation (abscopal effect) in aggressive clear cell histologies when standard chemotherapy fails. [@pubmed:36591227]

- Ovarian clear cell carcinoma is characterized by association with endometriosis, frequent ARID1A and PIK3CA alterations, chemoresistance to platinum-based regimens, and may benefit from strategies targeting angiogenesis, PI3K/AKT/mTOR, DNA damage response, or immune pathways; enrollment in clinical trials is encouraged. [@pubmed:33758607]

- A case report of recurrent ovarian clear cell carcinoma with ARID1A mutation demonstrated a remarkable response to third-line triplet therapy (olaparib + pembrolizumab + bevacizumab), supporting consideration of PARP inhibitor–immunotherapy–anti-VEGF combinations in selected, heavily pretreated clear cell cases, ideally within trials. [@pubmed:35401005]

- A novel ovarian clear cell carcinoma cell line (NUCOLL43) with extensive genomic loss of heterozygosity and cisplatin sensitivity in vitro highlights potential responsiveness to DNA-damaging agents and supports further exploration of platinum and DNA repair–targeted strategies in this histology. [@pubmed:30109783]

- Case series of ovarian clear cell carcinoma arising from endometriosis underscore the malignant potential of endometriosis, the often aggressive course of clear cell tumors, and the need for vigilant follow-up and timely intervention in endometriosis-associated ovarian masses. [@pubmed:37901720]</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Guideline+PubMed RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-19T08:09:44.496727&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:09:44.497083&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;efe856c0897d&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:09:44.784030&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:01.541598&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:01.548052&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=卵巢癌复发; histology=首先考虑为透明细胞癌; components=高级别腺癌\nPATHOLOGY: 部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\nPLATINUM: status=Resistant; pfi_days=56\nGENETICS: HRD=Unknown; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; note=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PAL…&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:38.053731&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Ovarian clear cell carcinoma, platinum-refractory after 6 cycles carboplatin; metastases to liver, pelvis/presacral area, mesentery, possible sacrum/right iliac bone; MMR intact (MLH1/MSH2/MSH6/PMS2+); need systemic options and trial eligibility given progression shortly post-platinum; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:38.053747&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:38.053749&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:38.053751&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:53.358781&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:53.358851&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:57.809094&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 595
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:10:57.809180&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:01.452443&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 551
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:01.452519&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:05.381117&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 477
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:05.381176&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:09.020490&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 455
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:09.020531&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:11:11.475947&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 520
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:15:03.119425&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2903
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:15:03.120431&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:15:25.921099&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: true
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:15:25.921139&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-19T08:18:02.280016&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1538
    }
  }
]</pre>
  </details>

</body>
</html>
